ClinicalTrials.gg
RecruitingNCT06701513Updated May 18, 2026

A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Recruiting at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Planned enrollment
10th of 14
350 · median 528
Started
2025
with 6 others
Observational
14 of 42
5 open now
Primary completion
2028-04
later than 5 of 13 live
Registered
35th of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 35th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients who have been diagnosed with moderate-to-severe plaque psoriasis and who intend to start deucravacitinib treatment in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Physician-reported diagnosis of moderate to severe plaque psoriasis
  • Be newly initiating deucravacitinib
  • Do not object to participate

Exclusion criteria

Exclusion Criteria:

  • Currently participating in or planning to participate in an interventional clinical trial
  • Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Participants that have initiated deucravacitinib treatment

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Physician's Global Assessment (PGA) 0/1 response

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  2. Dermatology Life Quality Index (DLQI) 0/1 response

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  3. Time from date of treatment initiation to date of discontinuation

    Time frame: Up to 24 months

Secondary outcomes

  1. Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  2. Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch

    Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

  3. Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain

    Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

  4. Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue

    Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24

  5. Physician's Global Assessment (PGA) score change from start of deucravacitinib treatment to follow-up

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  6. Dermatology Life Quality Index (DLQI) score of ≤5

    Time frame: Baseline and at months 1, 4, 12 18 (optional) and 24

  7. Body Surface Area (BSA) of ≤ 3%

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  8. Body Surface Area (BSA) of ≤ 1%

    Time frame: Baseline and at months 4, 12, 18 (optional), and 24

  9. Reasons for deucravacitinib treatment discontinuation

    Time frame: Up to 24 months

07

Study locations

39 of 48 sites recruiting
  • Chu Amiens Picardie - Site Sud
    Amiens, 80054, France
    Recruiting
    • Ali Dadban, Site 060 · Contact33322455841
  • Cabinet Médical Elisabeth Lion
    Angers, 49100, France
    Recruiting
    • ANGELIQUE MARCHAND, Site 009 · Contact
  • Ch Victor Dupouy
    Argenteuil, 95107, France
    Recruiting
    • EMMANUEL MAHE, Site 045 · Contact
  • Local Institution - 089
    Argenteuil, 95107, France
    Completed

    Not enrolling at this site — choose another above.

  • CH ARRAS
    Arras, 62000, France
    Recruiting
    • CELINE DESVIGNES, Site 010 · Contact
  • Cabinet Dermatologie
    Bordeaux, 33200, France
    Recruiting
    • VALERIE DORIZY-VUONG, Site 041 · Contact
  • Cabinet Dermatologie
    Bordeaux, 33200, France
    Recruiting
    • CHRISTELLE PRUVOST BALLAND, Site 048 · Contact
  • Centre Hospitalier William Morey - Hématologie
    Chalon-sur-Saône, 71100, France
    Recruiting
    • MARIE DHERS, Site 001 · Contact
  • Local Institution - 053
    Clermont-Ferrand, 63000, France
    Completed

    Not enrolling at this site — choose another above.

  • CHU Dijon
    Dijon, 21000, France
    Recruiting
    • Camille LELEU, Site 002 · Contact33 3 80 29 33 36
  • Local Institution - 077
    Dijon, 21000, France
    Not yet recruiting
    • Site 077 · Contact
  • CHU Grenoble Alps, Service de Dermatologie
    La Tronche, 38700, France
    Recruiting
    • Julie Charles, Site 011 · Contact+33476766493
  • Local Institution - 014
    Le Mans, 72037, France
    Not yet recruiting
    • Site 014 · Contact
  • CH Emile Roux
    Le Puy-en-Velay, 43000, France
    Recruiting
    • CHARLINE GARCIA, Site 074 · Contact
  • Centre Hospitalier Lens
    Lens, 62307, France
    Recruiting
    • ELENA KARIMOVA, Site 039 · Contact
  • Centre de santé Filieris
    Marcq-en-Barœul, 59700, France
    Recruiting
    • MARION STEFANSKI, Site 004 · Contact
  • Hopital Saint Eloi
    Montpellier, 34295, France
    Recruiting
    • CELINE GIRARD, Site 036 · Contact
  • Tagast 41
    Nice, 06000, France
    Recruiting
    • Abdallah Khemis, Site 012 · Contact+33492036225
  • Ch Georges Renon
    Niort, 79021, France
    Recruiting
    • CAROLINE JADE CLERC, Site 070 · Contact
  • Ch Georges Renon
    Niort, 79021, France
    Recruiting
    • JEREMY GOTTLIEB, Site 008 · Contact
  • Hopital Caremeau
    Nîmes, 30900, France
    Recruiting
    • BLANCHE BERGERET, Site 062 · Contact
  • Cabinet de dermatologie
    Paris, 75012, France
    Recruiting
    • MATHILDE KEMULA, Site 073 · Contact
  • Local Institution - 086
    Paris, 75012, France
    Completed

    Not enrolling at this site — choose another above.

  • Hôpital Privé Francheville
    Périgueux, 24000, France
    Recruiting
    • MARIE MASSON REGNAULT, Site 078 · Contact
  • Centre Hospitalier de Roubaix
    Roubaix, 59056, France
    Recruiting
    • OLIVIER CARPENTIER, Site 046 · Contact
  • Centre Hospitalier de Roubaix
    Roubaix, 59056, France
    Recruiting
    • SARAH JABRAN MAANAOUI, Site 047 · Contact
  • Local Institution - 031
    Rouen, 76031, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 065
    Saint-Germain-en-Laye, 78100, France
    Not yet recruiting
    • Site 065 · Contact
  • Hia Begin
    Saint-Mandé, 94163, France
    Recruiting
    • ANNE CLAIRE FOUGEROUSSE, Site 051 · Contact
  • Centre Dermatologique
    Saint-Maur-des-Fossés, 94100, France
    Recruiting
    • CHLOE CHARPENTIER, Site 072 · Contact
  • Hia Sainte Anne
    Toulon, 83800, France
    Recruiting
    • AUDE VALOIS, Site 054 · Contact
  • Hia Sainte Anne
    Toulon, 83800, France
    Recruiting
    • Thierry Boye, Site 055 · Contact33483162916
  • Hopital Larrey
    Toulouse, 31059, France
    Recruiting
    • MAELLA SEVERINO FREIRE, Site 037 · Contact
  • Hopital Larrey
    Toulouse, 31059, France
    Recruiting
    • Cristina Livideanu, Site 021 · Contact+33567771452
  • Hopital Larrey
    Toulouse, 31059, France
    Recruiting
    • Carle Paul, Site 005 · Contact+33567778140
  • Hopitaux de Brabois
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
    • ANNE CLAIRE BURSZTEJN, Site 061 · Contact
  • Hopitaux de Brabois
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
    • EMMANUELLE MELGAR, Site 064 · Contact
  • Médipôle Hôpital Mutualiste
    Villeurbanne, 69100, France
    Recruiting
    • CATHERINE GOUJON-HENRY, Site 003 · Contact
  • Médipôle Hôpital Mutualiste
    Villeurbanne, 69100, France
    Recruiting
    • XAVIER MARCELLIN, Site 006 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • NICOLE JOUAN, Site 015 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • BENOIT BEN SAID, Site 016 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • JOSIANE PARIER, Site 038 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • MORAD LAHFA, Site 044 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • ANNE CAROLINE COTTENCIN, Site 025 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • MARC REVERTE, Site 029 · Contact
  • Cabinet Medical
    La Chaux-de-Fonds, 2300, Switzerland
    Recruiting
    • Mireille Ruer-Mulard, Site 007 · Contact+33442800590
  • Local Institution - 056
    La Chaux-de-Fonds, 2300, Switzerland
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 059
    La Chaux-de-Fonds, 2300, Switzerland
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2028, 39 months after the start.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 39 months is close to that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartActual
Jan 29, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701513
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jan 29, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
May 18, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion